MedPath

FDA Approves PTC Therapeutics' Gene Therapy Kebilidi for AADC Deficiency

• The FDA has approved eladocagene exuparvovec-tneq (Kebilidi), a gene therapy developed by PTC Therapeutics, for treating AADC deficiency in adult and pediatric patients. • Kebilidi is the first FDA-approved gene therapy for AADC deficiency, a rare genetic disorder affecting neurotransmitter production and causing severe developmental delays. • The therapy involves direct brain infusion to deliver a functional DDC gene, enhancing dopamine production and improving motor function in treated patients. • Clinical trials demonstrated improved motor function in patients treated with Kebilidi compared to untreated individuals, supporting the accelerated approval and ongoing confirmatory trial.

The FDA has granted approval to eladocagene exuparvovec-tneq (Kebilidi, PTC Therapeutics), a novel adeno-associated virus vector-based gene therapy, for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency in both adult and pediatric patients. This marks a significant advancement as Kebilidi becomes the first FDA-approved gene therapy specifically indicated for this rare and debilitating genetic disorder.
AADC deficiency results from mutations in the DDC gene, impairing the synthesis of dopamine and leading to severe developmental delays and neurological abnormalities. Symptoms typically manifest within the first few months of life, including delays in motor function, hypotonia, and cognitive impairments. The newly approved gene therapy offers a potential avenue to address the underlying cause of the deficiency by delivering a functional copy of the DDC gene directly to the brain.

How Kebilidi Works

Kebilidi is administered through four infusions during a single surgical session directly into the putamen, a region of the brain crucial for motor control. This procedure requires specialized expertise in pediatric stereotactic neurosurgery. Once infused, the gene therapy promotes the expression of the AADC enzyme, subsequently increasing dopamine levels in the brain. Dopamine is a critical neurotransmitter involved in movement, attention, learning, and memory.

Clinical Trial Data

The safety and efficacy of eladocagene exuparvovec-tneq were evaluated in an open-label, single-arm clinical study involving 13 pediatric patients with confirmed AADC deficiency. All patients exhibited no gross motor function at the study's outset and had decreased AADC activity in plasma. When compared to untreated patients, those treated with eladocagene exuparvovec-tneq showed notable improvements in gross motor function. At week 48, eight out of 12 treated patients demonstrated improved motor skills, a result not observed in the untreated cohort with severe AADC deficiency.

Regulatory Context

Eladocagene exuparvovec-tneq received accelerated approval, priority review, orphan drug designation, and a rare pediatric disease priority review voucher from the FDA. Continued approval is contingent upon verification and description of clinical benefit, such as the durability of improved symptoms, in an ongoing confirmatory clinical trial.

Device Authorization

In conjunction with the gene therapy approval, the FDA also authorized the SmartFlow Neuro Cannula (ClearPoint Neuro), an infusion tube designed for precise delivery of eladocagene exuparvovec-tneq into the brain's parenchymal tissue. The SmartFlow Neuro Cannula is currently the only FDA-authorized device indicated for use in the administration of Kebilidi.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating Aromatic L-Amino Acid Decarboxylase (AADC) deficiency in adults and children.
Kebilidi, an adeno-associated virus vector-based gene therapy, is the first FDA-approved treatment of its kind for this rare genetic disorder affecting neurotransmitter production.

FDA Approves First Brain-Delivered Gene Therapy for AADC Deficiency

Eladocagene exuparvovec (Kebilidi) receives accelerated FDA approval as the first gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
The therapy delivers a functioning human _DDC_ gene directly into the brain's putamen to increase AADC enzyme production and restore dopamine synthesis.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy with Direct Brain Administration for AADC Deficiency

The FDA granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for AADC deficiency, marking the first gene therapy approved in the U.S. for direct brain administration.
Kebilidi, a gene replacement therapy, is indicated for both children and adults with AADC deficiency, addressing the full spectrum of disease severity by restoring dopamine synthesis.

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for aromatic I-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi delivers the DDC gene directly to the brain, enabling dopamine synthesis and improving motor development milestones in patients with AADC deficiency.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.
Kebilidi, developed by PTC Therapeutics, is the first gene therapy approved in the U.S. that is directly administered to the brain via a stereotactic surgical procedure.

FDA Approves Eladocagene Exuparvovec-Tneq (Kebilidi) for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for both adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Approval was based on a clinical trial of 13 pediatric patients, where 8 of 12 treated individuals showed improved gross motor function compared to untreated individuals.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in patients aged 18 months and older.
Kebilidi is the first gene therapy administered directly to the brain to be approved in the United States for this rare genetic disorder.

FDA Approves PTC Therapeutics' Gene Therapy KEBILIDI for AADC Deficiency

The FDA has granted accelerated approval to KEBILIDI (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first FDA-approved gene therapy directly administered to the brain.
KEBILIDI, developed by PTC Therapeutics, is indicated for both children and adults with AADC deficiency, addressing a critical unmet need across the spectrum of disease severity.

FDA Approves Kebilidi Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in both children and adults.
Kebilidi, a gene replacement therapy, is administered directly into the brain to restore dopamine production, addressing the underlying genetic defect.

Reference News

[1]
FDA Approves PTC Therapeutics' Gene Therapy for AADC Deficiency
biopharminternational.com · Nov 18, 2024

FDA approved eladocagene exuparvovec-tneq (Kebilidi), the first gene therapy for aromatic L-amino acid decarboxylase (AA...

[2]
FDA Approves Direct-to-Brain Gene Therapy for AADC ...
aabb.org · Nov 14, 2024

FDA approved eladocagene exuparvovec-tneq, the first gene therapy for AADC deficiency, a rare genetic disorder. Administ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy